| Phosphatidylinositol-3-OH kinase direct target of Ras P Rodriguez-Viciana, PH Warne, R Dhand, B Vanhaesebroeck, I Gout, ... Nature 370 (6490), 527-532, 1994 | 2670 | 1994 |
| The PI3K–PDK1 connection: more than just a road to PKB B Vanhaesebroeck, DR Alessi Biochemical Journal 346 (3), 561-576, 2000 | 2228 | 2000 |
| Synthesis and function of 3-phosphorylated inositol lipids B Vanhaesebroeck, SJ Leevers, K Ahmadi, J Timms, R Katso, PC Driscoll, ... Annual review of biochemistry 70 (1), 535-602, 2001 | 2137 | 2001 |
| The emerging mechanisms of isoform-specific PI3K signalling B Vanhaesebroeck, J Guillermet-Guibert, M Graupera, B Bilanges Nature reviews Molecular cell biology 11 (5), 329-341, 2010 | 1979 | 2010 |
| Phosphoinositide 3-kinases: a conserved family of signal transducers B Vanhaesebroeck, SJ Leevers, G Panayotou, MD Waterfield Trends in biochemical sciences 22 (7), 267-272, 1997 | 1361 | 1997 |
| Signaling by distinct classes of phosphoinositide 3-kinases B Vanhaesebroeck, MD Waterfield Experimental cell research 253 (1), 239-254, 1999 | 1217 | 1999 |
| Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice K Okkenhaug, A Bilancio, G Farjot, H Priddle, S Sancho, E Peskett, ... Science 297 (5583), 1031-1034, 2002 | 1167 | 2002 |
| Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. K Schulze-Osthoff, AC Bakker, B Vanhaesebroeck, R Beyaert, WA Jacob, ... Journal of Biological Chemistry 267 (8), 5317-5323, 1992 | 1129 | 1992 |
| PI3K signalling: the path to discovery and understanding B Vanhaesebroeck, L Stephens, P Hawkins Nature reviews Molecular cell biology 13 (3), 195-203, 2012 | 1076 | 2012 |
| PI3K in lymphocyte development, differentiation and activation K Okkenhaug, B Vanhaesebroeck Nature Reviews Immunology 3 (4), 317-330, 2003 | 983 | 2003 |
| Signalling through phosphoinositide 3-kinases: the lipids take centre stage SJ Leevers, B Vanhaesebroeck, MD Waterfield Current opinion in cell biology 11 (2), 219-225, 1999 | 925 | 1999 |
| Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase B Stoyanov, S Volinia, T Hanck, I Rubio, M Loubtchenkov, D Malek, ... Science 269 (5224), 690-693, 1995 | 912 | 1995 |
| Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction MP Wymann, G Bulgarelli-Leva, MJ Zvelebil, L Pirola, B Vanhaesebroeck, ... Molecular and cellular biology, 1996 | 901 | 1996 |
| Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. P Rodriguez‐Viciana, PH Warne, B Vanhaesebroeck, MD Waterfield, ... The EMBO journal 15 (10), 2442-2451, 1996 | 786 | 1996 |
| p110δ, a novel phosphoinositide 3-kinase in leukocytes B Vanhaesebroeck, MJ Welham, K Kotani, R Stein, PH Warne, ... Proceedings of the National Academy of Sciences 94 (9), 4330-4335, 1997 | 603 | 1997 |
| Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration M Graupera, J Guillermet-Guibert, LC Foukas, LK Phng, RJ Cain, ... Nature 453 (7195), 662-666, 2008 | 597 | 2008 |
| Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study TI Coulter, A Chandra, CM Bacon, J Babar, J Curtis, N Screaton, ... Journal of Allergy and Clinical Immunology 139 (2), 597-606. e4, 2017 | 596 | 2017 |
| Signalling by PI3K isoforms: insights from gene-targeted mice B Vanhaesebroeck, K Ali, A Bilancio, B Geering, LC Foukas Trends in biochemical sciences 30 (4), 194-204, 2005 | 579 | 2005 |
| Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation LC Foukas, M Claret, W Pearce, K Okkenhaug, S Meek, E Peskett, ... Nature 441 (7091), 366-370, 2006 | 564 | 2006 |
| Inactivation of PI (3) K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer K Ali, DR Soond, R Pineiro, T Hagemann, W Pearce, EL Lim, H Bouabe, ... Nature 510 (7505), 407-411, 2014 | 533 | 2014 |
Klaus OkkenhaugDivision of Immunology, Department of Pathology, University of CambridgeVerified email at cam.ac.uk
